Dupixent®

DRUG8 trials

Conditions

Allergic RhinoconjunctivitisAsthmaAtopic DermatitisAtopic Dermatitis (AD)Chronic Rhinosinusitis With Nasal PolyposisGrass Pollen AllergyNasal Polyps

Phase 1

A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

CompletedNCT06614907

Qilu Pharmaceutical Co., Ltd.Atopic Dermatitis

Start: 2024-08-31End: 2024-12-27Updated: 2025-03-12

Phase 2

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

CompletedNCT04502966

National Institute of Allergy and Infectious Diseases (NIAID)Allergic Rhinoconjunctivitis, Grass Pollen Allergy

Start: 2020-11-05End: 2025-02-20Updated: 2026-04-27

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

CompletedNCT05470114

LEO PharmaAtopic Dermatitis

Start: 2022-05-19End: 2023-10-09Updated: 2025-03-11

Phase 3

A Phase Ⅲ Comparative Study of QL2108 to Dupixent®

Not yet recruitingNCT06884891

Qilu Pharmaceutical Co., Ltd.Atopic Dermatitis

Start: 2025-04-30End: 2028-04-30Target: 520Updated: 2025-03-21

A Phase III Study of GS101 Injection to Dupixent®

Not yet recruitingNCT07386743

Jiangsu Genscend Biopharmaceutical Co., LtdAtopic Dermatitis (AD)

Start: 2026-02-01End: 2028-01-01Target: 572Updated: 2026-02-04

Phase 4

Complete Remission After Treatment With Biologics for Nasal Polyps

RecruitingNCT07268313

Rigshospitalet, DenmarkNasal Polyps

Start: 2025-04-03End: 2027-06-01Target: 66Updated: 2025-12-05

Unknown Phase

Registry of Asthma Patients Initiating DUPIXENT®

CompletedNCT04287621

Regeneron PharmaceuticalsAsthma

Start: 2020-03-02End: 2026-04-27Updated: 2026-06-04

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Active, not recruitingNCT04959448

Regeneron PharmaceuticalsChronic Rhinosinusitis With Nasal Polyposis

Start: 2021-08-12End: 2027-03-25Updated: 2026-07-13

PubMed2026-04-30

Baseline disease characteristics among patients with chronic rhinosinusitis with nasal polyps in AROMA: A global registry study

Allergy and Asthma Proceedings2025-09-011 citations

Safety and Efficacy of Dupilumab in Adults and Adolescents With Asthma in the RAPID Registry

American Journal of Respiratory and Critical Care Medicine2025-05-01

Dupilumab Improves Health-related Quality of Life and Asthma Control in Patients With and Without Coexisting Type 2 Conditions: Results from the RAPID Study

American Journal of Respiratory and Critical Care Medicine2025-05-01

Baseline Corticosteroid use and surgery history among patients with chronic Rhinosinusitis with nasal polyps in the AROMA registry

Laryngo-Rhino-Otologie2024-04-19

Kortikosteroid-Anwendung und OP-Vorgeschichte zu Studienbeginn bei Patienten mit chronischer Rhinosinusitis mit Nasenpolypen im globalen Register AROMA

Laryngo-Rhino-Otologie2024-04-19

Baseline characteristics of patients with asthma and prior systemic corticosteroid use in the RAPID (dupilumab) registry

2023-09-09

Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry

Advances in Therapy2023-01-1011 citations

S128 Baseline characteristics of patients with asthma treated with dupilumab in a real-world setting: results from the RAPID registry

2022-11-01

AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps

ERJ Open Research2022-10-0112 citations